RESIST-PC二期试验:177Lu-PSMA-617治疗mCRPC的肿瘤与器官剂量估算
RESIST-PC前瞻性随机二期试验的剂量学分析,评估两种注射活度方案(6.0或7.4 GBq/周期)的177Lu-PSMA-617在转移性去势抵抗性前列腺癌患者中的器官和肿瘤吸收剂量。48例患者有完整影像数据集,肾脏、唾液腺和肝脏平均吸收剂量在可耐受范围内,肿瘤吸收剂量在患者间和患者内变异大,且前列腺特异性抗原反应与肿瘤吸收剂量呈显著负相关。
要点
- 肾脏、下颌下腺、腮腺和肝脏平均吸收剂量分别为0.29、0.23、0.26和0.11 Gy/GBq。
- 两种注射活度方案间器官或肿瘤吸收剂量无显著差异。
- 前列腺特异性抗原反应与肿瘤吸收剂量呈显著负相关(ρ=-0.404,P=0.006)。
核心结论
- 混合影像协议剂量学分析显示器官吸收剂量在可耐受范围内,肿瘤吸收剂量在患者间和患者内变异大,与注射活度无关。
研究设计与样本
- RESIST-PC前瞻性随机二期试验的剂量学分析,双中心研究,患者1:1随机接受6.0或7.4 GBq的177Lu-PSMA-617每周期最多4周期。
- 共64例患者中48例(6.0 GBq组16例,7.4 GBq组32例)有完整影像数据集并纳入分析。
- 第一周期使用混合协议(平面+SPECT)采集γ图像,平面全身闪烁显像在4、24、48和72小时(可选168小时)采集,注射后24小时行定量SPECT/CT。
主要发现
- 肾脏、下颌下腺、腮腺和肝脏平均吸收剂量分别为0.29±0.11、0.23±0.18、0.26±0.15和0.11±0.09 Gy/GBq。
- 两种注射活度方案间器官或肿瘤吸收剂量无显著差异。
- 共分析358个病灶(中位7个/患者,范围0-18个/患者);骨病灶(n=304)在6.0 GBq组(n=121)和7.4 GBq组(n=183)的平均吸收剂量分别为1.90±1.83和1.64±1.77 Gy/GBq。
- 淋巴结病灶(n=35)在6.0 GBq组(n=22)和7.4 GBq组(n=13)的平均吸收剂量分别为5.61±3.93和1.79±1.96 Gy/GBq;仅7.4 GBq队列出现肝脏病灶,平均吸收剂量为1.59±1.45 Gy/GBq(n=19)。
- 前列腺特异性抗原反应与肿瘤吸收剂量呈显著负相关(ρ=-0.404,P=0.006)。
关键数值与推荐
- 肾脏平均吸收剂量0.29±0.11 Gy/GBq,下颌下腺0.23±0.18 Gy/GBq,腮腺0.26±0.15 Gy/GBq,肝脏0.11±0.09 Gy/GBq。
- 骨病灶平均吸收剂量6.0 GBq组1.90±1.83 Gy/GBq,7.4 GBq组1.64±1.77 Gy/GBq。
- 淋巴结病灶平均吸收剂量6.0 GBq组5.61±3.93 Gy/GBq,7.4 GBq组1.79±1.96 Gy/GBq。
- 肝脏病灶平均吸收剂量1.59±1.45 Gy/GBq(仅7.4 GBq组)。
- 前列腺特异性抗原反应与肿瘤吸收剂量相关系数ρ=-0.404,P=0.006。
临床怎么用
- 混合影像协议可用于177Lu-PSMA-617治疗中器官和肿瘤吸收剂量的估算。
- 肿瘤吸收剂量在患者间和患者内变异大,提示可能需要个体化剂量学评估。
- 前列腺特异性抗原反应与肿瘤吸收剂量负相关,支持剂量-反应关系。
局限性
- 未进行部分容积校正。
- 仅第一周期进行剂量学评估。
- 样本量有限(48例分析)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This is a dosimetry analysis of the prospective randomized phase 2 trial RESIST-PC which evaluated the efficacy and safety of 2 injected activity regimens of [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer. Methods: This biinstitutional study randomized patients with metastatic castration-resistant prostate cancer to receive either 6.0 or 7.4 GBq of [177Lu]Lu-PSMA-617 per cycle for up to 4 cycles (1:1 randomization). The γ-images were obtained at the first cycle using a hybrid protocol (planar + SPECT). Whole-body planar scintigraphy images were acquired at 4, 24, 48, and 72 h (optionally at 168 h), and a quantitative SPECT/CT was performed at 24 h postinjection. Absorbed doses (ADs) were calculated for the kidneys, salivary glands, liver, and tumors. Planar time-activity curves were derived on a per-region basis from counts in the serial scans, with exponential curve fit selection based on Akaike information criterion. Quantitative SPECT data per region were scaled by the planar time-activity data and then convolved with a voxel-S value dose kernel to yield AD estimates. No partial volume corrections were applied. Adverse events and efficacy data were correlated to the calculated AD. Results: A total of 48 of 64 patients (16 treated with 6.0 GBq vs. 32 in the 7.4-GBq arm) had complete imaging datasets and were analyzed. The mean kidney, submandibular, parotid, and liver ADs were 0.29 ± 0.11, 0.23 ± 0.18, 0.26 ± 0.15, and 0.11 ± 0.09 Gy/GBq, respectively. There was no significant difference in organ or tumor ADs between arms. In total, 358 lesions were included in the analysis (median, 7/patient [range, 0-18/patient]). The mean AD to bone lesions (n = 304) was 1.90 ± 1.83 and 1.64 ± 1.77 Gy/GBq for the 6.0-GBq (n = 121) and 7.4-GBq (n = 183) groups, respectively. For lymph node lesions (n = 35), mean ADs were 5.61 ± 3.93 Gy/GBq (n = 22) and 1.79 ± 1.96 Gy/GBq (n = 13) for the 6.0- and 7.4-GBq groups, respectively. Only the 7.4-GBq cohort presented liver lesions; mean AD was 1.59 ± 1.45 Gy/GBq (n = 19). A statistically significant inverse correlation was observed between prostate-specific antigen response and tumor AD (ρ = -0.404, P = 0.006). Conclusion: In the RESIST-PC prospective phase 2 trial, dosimetry analyses using a hybrid imaging protocol revealed organ ADs within tolerable ranges, and tumor ADs varied widely on the inter- and intrapatient level regardless of injected activity.
引用
- Ells Z, Meyer C, Masri K, et al. Tumor and Organ Dose Estimates from 177Lu-PSMA-617 Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the RESIST-PC Phase 2 Trial. J Nucl Med. 2026. PMID: 42532646. doi:10.2967/jnumed.126.272574
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。